Article in Balkan medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors at 16 institutions in 2 countries.
Murat SayanClinical Laboratory, PCR Unit, Kocaeli University School of Medicine, Kocaeli, TurkeyORCID 0000-0002-4374-7193
Müge ÖzgülerClinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Elazığ Fethi Sekin City Hospital, Elazığ, TurkeyORCID 0000-0002-2689-7931
Figen Sarıgül YıldırımClinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Antalya Training and Research Hospital, Antalya, TurkeyORCID 0000-0001-8646-2203
Taner YıldırmakClinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Okmeydanı Training and Research Hospital, İstanbul, TurkeyORCID 0000-0001-7006-7161
Alper GündüzClinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Şişli Etfal Training and Research Hospital, İstanbul, TurkeyORCID 0000-0001-9154-844X
Başak DokuzoğuzClinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Ankara Training and Research Hospital, Ankara, TurkeyORCID 0000-0001-7403-3292
Mustafa Kemal ÇelenDepartment of Infectious Diseases and Clinical Microbiology, Dicle University School of Medicine, Diyarbakır, TurkeyORCID 0000-0001-5876-2241
Dilara İnanDepartment of Infectious Diseases and Clinical Microbiology, Akdeniz University School of Medicine, Antalya, TurkeyORCID 0000-0002-7551-6728
Yasemin HeperDepartment of Infectious Diseases and Clinical Microbiology, Uludağ University School of Medicine, Bursa, TurkeyORCID 0000-0002-6635-5416
Gülden ErsözDepartment of Infectious Diseases and Clinical Microbiology, Mersin University School of Medicine, Mersin TurkeyORCID 0000-0003-2836-3586
İlkay KaraoğlanDepartment of Infectious Diseases and Clinical Microbiology, Gaziantep University School of Medicine, Gaziantep, TurkeyORCID 0000-0002-6767-4523
Nurgül CeranClinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, İstanbul, TurkeyORCID 0000-0002-6886-8266
Aydın DeveciDepartment of Infectious Diseases and Clinical Microbiology, Ondokuz Mayıs University School of Medicine, Samsun, TurkeyORCID 0000-0001-8057-6445
Servet ÖztürkClinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, İstanbul, TurkeyORCID 0000-0002-9114-5090
Selda Sayın KutluDepartment of Infectious Diseases and Clinical Microbiology, Pamukkale University School of Medicine, Denizli, TurkeyORCID 0000-0002-6443-3628
Hülya Özkan ÖzdemirDepartment of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bozyaka Training and Research Hospital, İzmir, TurkeyORCID 0000-0002-0041-1710
Ayhan AkbulutDepartment of Infectious Diseases and Clinical Microbiology, Fırat University School of Medicine, Elazığ, TurkeyORCID 0000-0003-2560-3265
Saadet YazıcıClinic of Infectious Diseases and Clinical Microbiology, Medeniyet University, Göztepe Training and Research Hospital, İstanbul, TurkeyORCID 0000-0003-2591-9307
Alper ŞenerDepartment of Infectious Diseases and Clinical Microbiology, Onsekiz Mart University School of Medicine, Çanakkale, TurkeyORCID 0000-0003-2774-8601
Atahan ÇağatayDepartment of Infectious Diseases and Clinical Microbiology, İstanbul University School of Medicine, İstanbul, TurkeyORCID 0000-0002-3051-8199
Serhat ÜnalDepartment of Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, TurkeyORCID 0000-0003-1184-4711
Sağlık Bilimleri Üniversitesi · TRBursa Uludağ Üni̇versi̇tesi̇ · TRÇanakkale Onsekiz Mart Üniversitesi · TRDicle University · TRElazığ Eğitim ve Araştırma Hastanesi · TRFırat University · TRGaziantep University · TRHacettepe University · TRIstanbul Medeniyet University · TRIstanbul University · TRIzmir University · TRKocaeli Üniversitesi · TRMersin Üniversitesi · TRNear East University · CYOndokuz Mayıs University · TRPamukkale University · TR
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Background: Because of their similar modes of transmission, the simultaneous infection of viral hepatitis and human immunodeficiency virus are increasingly seen as a big problem related to human health. Aims: To determine the drug mutations in hepatitis B virus and/or hepatitis C virus co-infected human immunodeficiency virus-1 patients in Turkey. Study Design: Retrospective cross-sectional study. Methods: The present study was conducted between 2010 and 2017. HBsAg, anti-hepatitis C virus, and anti-human immunodeficiency virus were tested with ELISA. All anti-human immunodeficiency virus positive results by ELISA were verified for anti-human immunodeficiency virus positivity by a Western blot test, and Anti-human immunodeficiency virus positive patients with HBsAg and/or anti-hepatitis C virus positivity were included in the study. Subtyping and genotypic resistance analyses were performed by population sequencing of the viral protease and reverse transcriptase regions of the human immunodeficiency virus-1 pol gene. Results: We detected 3896 human immunodeficiency virus-1 positive patients whose sera were sent from numerous hospitals across the country to our polymerase chain reaction unit for detection of drug resistance mutations and whose molecular laboratory tests were completed. Viral hepatitis co-infections were detected in 4.3% (n=170) of patients. Hepatitis B virus and hepatitis C virus co-infection were observed in 3.2% and 0.5% of all human immunodeficiency virus-1 infected patients, respectively. The major human immunodeficiency virus-1 subtype detected was group M, subtype B (62.9%). However, 13.5% of drug resistance mutation motifs were found in human immunodeficiency virus-1 genomes of patients included in the study. Conclusion: Due to similar transmission routes, HIV1 patients are at risk of hepatitis B and C virus co-infection. However, antiretroviral drug resistance mutation model is similar to patients with hepatitis negative.
Indexed as
CoinfectionCross-Sectional StudiesHepacivirusHepatitis BHepatitis B virusHepatitis CHIV InfectionsHumansPolymerase Chain ReactionRetrospective StudiesTurkeyCo-infectionhepatitis B virushepatitis C virusHIV-1molecular epidemiology
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Molecular Identification of HIV-1 in the Presence of Hepatitis B Virus and Hepatitis C Virus Co-infections · full record | OpenQuestion